EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems

Antoine Hakim, Benjamin Guido, Lokesh Narsineni, Ding-Wen Chen, Marianna Foldvari

Advanced Drug Delivery Reviews · 2023-05 · 196 · 114781

DOI: 10.1016/j.addr.2023.114781 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-05. Verfasst von Antoine Hakim und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada. Hauptthemen laut MEDLINE: Neuroprotection, Glaucoma. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 172 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, NSERC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is the result of the gradual death of retinal ganglion cells (RGCs) whose axons form the optic nerve. Elevated intraocular pressure (IOP) is a major risk factor that contributes to RGC apoptosis and axonal loss at the lamina cribrosa, resulting in progressive reduction and eventual anterograde-retrograde transport blockade of neurotrophic factors. Current glaucoma management mainly focuses on pharmacological or surgical lowering of IOP, to manage the only modifiable risk factor. Although IOP reduction delays disease progression, it does not address previous and ongoing optic nerve degeneration. Gene therapy is a promising direction to control or modify genes involved in the pathophysiology of glaucoma. Both viral and non-viral gene therapy delivery systems are emerging as promising alternatives or add-on therapies to traditional treatments for improving IOP control and providing neuroprotection. The specific spotlight on non-viral gene delivery systems shows further progress toward improving the safety of gene therapy and implementing neuroprotection by targeting specific tissues and cells in the eye and specifically in the retina.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroprotectionGlaucomaHumansAnimalsIntraocular PressureRetinaGenetic TherapyDisease Models, Animal

Stichwörter der Autor:innen

BDNFGene therapyGlaucomaNeuroprotectionNon-viral gene deliveryRetina delivery

Autor:innen und Institutionen

  • School of Pharmacy, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.
  • School of Pharmacy, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada; Waterloo Institute of Nanotechnology and Center for Bioengineering and Biotechnology, University of Waterloo, 200 Uni…

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • NSERC

Zitieren

APA

Hakim, A., Guido, B., Narsineni, L., Chen, D. W., & Foldvari, M. (2023). Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems. Advanced Drug Delivery Reviews, 196, 114781. https://doi.org/10.1016/j.addr.2023.114781

Vancouver

Hakim A, Guido B, Narsineni L, Chen DW, Foldvari M. Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems. Advanced Drug Delivery Reviews. 2023;196:114781. doi:10.1016/j.addr.2023.114781

BibTeX
@article{Hakim2023,
  author = {Hakim, Antoine and Guido, Benjamin and Narsineni, Lokesh and Chen, Ding-Wen and Foldvari, Marianna},
  title = {Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {196},
  pages = {114781},
  doi = {10.1016/j.addr.2023.114781}
}
Kostenlos starten →